Earendil Labs bags $787m to supercharge AI-driven biologics pipeline
Capital infusion to accelerate Earendil’s R&D platform
Capital infusion to accelerate Earendil’s R&D platform
The Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients
The company plans to submit the vaccine for regulatory review
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington
The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
Subscribe To Our Newsletter & Stay Updated